Book contents
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
10 - Definition of hyperandrogenism
Published online by Cambridge University Press: 05 July 2014
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
Summary
The definition of polycystic ovary syndrome (PCOS) has been based on a combination of three characteristics ever since Stein and Leventhal described the first cases in 1935. At that time, no methods for serum androgen measurement were available and the disorder was based on enlarged polycystic ovaries, acne, hirsutism and amenorrhoea. Since then, there have been numerous attempts at defining the syndrome, all of which have attempted to be as inclusive as possible of the myriad of phenotypes that comprise PCOS. There have been three formal definitions over the past two decades that have proposed a combination of clinical, biochemical and imaging criteria (see Table 10.1) but these, as we have argued in the past, are still too vague to pin down the syndrome.
Hyperandrogenism in the context of PCOS is a term used loosely to encompass both the clinical features of acne, hirsuties and androgenic alopecia and the laboratory evidence of hyperandrogenaemia. The clinical features are due to androgenic stimulation of the cutaneous pilosebaceous unit but the nature of acne, hirsuties and balding demonstrates that, even within an individual, the response is heterogeneous, so wide variations between women can only be expected and this defies an easy definition. The problem with hyperandrogenaemia is no easier: which androgen(s) should be measured, how often should it/they be measured and when in the menstrual cycle. There also remains the confusion created by the imprecise use of the terms hyperandrogenism and hyperandrogenaemia.
Keywords
- Type
- Chapter
- Information
- Current Management of Polycystic Ovary Syndrome , pp. 117 - 124Publisher: Cambridge University PressPrint publication year: 2010
- 1
- Cited by